Symic Bio Appoints Hicham Alaoui, Ph.D., as Senior Vice President of Discovery Biology

NovaQuest Capital Management to Acquire Viamet Pharmaceuticals and the VT-1161 Antifungal Program

Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300

Sutro Antibody Effectively Targets CD74 in Lymphoma & Multiple Myeloma Preclinical Studies

Aileron Therapeutics Presents New Data on ALRN-6924 in Oral Presentations at 2017 American Society of Hematology Meeting

Aeglea BioTherapeutics Doses First Pediatric Patient with Arginase 1 Deficiency in its Phase 1/2 Trial with Pegzilarginase (AEB1102)

Protagonist Therapeutics Initiates Phase 1 Trial of Oral Peptide IL-23 Receptor Antagonist, PTG-200

Symic​ ​Bio​ ​Appoints​ ​Wayne​ ​Froland,​ ​Ph.D.,​ ​as​ ​Executive​ ​Vice​ ​President​ ​of Technical​ ​Operations

Hydra Biosciences TRPC 4/5 Inhibitor now investigated in clinic for Central Nervous System Disorders

Aeglea BioTherapeutics to Present Preclinical Data at 2017 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Symic Bio Announces Results from the Phase 1/2 SHIELD Trial of SB-030 in Peripheral Vascular Disease

Aileron Therapeutics Announces Oral Presentations on Lead Product Candidate ALRN-6924 at the 59th American Society of Hematology Annual Meeting

Kymera Therapeutics Announces Series A to Advance Novel Therapeutic Modality and Develop Innovative Therapies

Viamet to Present Data Demonstrating the Efficacy and Safety of VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis at ISIDOG Congress 2017

Esanex Announces First Patient Dosed in an Open-Label Study of SNX-5422 in Chronic Lymphocytic Leukemia

Aeglea BioTherapeutics Announces Clinical Collaboration with Merck to Evaluate the Combination of Aeglea’s AEB1102 (pegzilarginase) with Merck’s KEYTRUDA® (pembrolizumab) for the Treatment of Small Cell Lung Cancer

Sutro Marks Two Drug Development Milestones

Protagonist Therapeutics Prices Public Offering of Common Stock

Nimbus Therapeutics and Celgene Enter Long-Term Strategic Immunology Alliance to Develop Programs for Patients with Autoimmune Disorders

Protagonist Therapeutics Announces Preliminary Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300

Cavion Announces First Patient Enrolled in Its Multi-Center Phase 2 Clinical Trial in Essential Tremor

Aeglea BioTherapeutics Doses Two Patients in Repeat Dose Part of Phase 1/2 Clinical Trial for the Treatment of Arginase 1 Deficiency

Celgene Corporation Exercised Option to Extend Strategic Collaboration Scope and Term with Forma Therapeutics

Coherus Biosciences Announces Positive Topline Results for Clinical Pharmacokinetic Bioequivalence Study for CHS-1420

Protagonist Therapeutics Announces Closing of Janssen License and Collaboration Agreement for PTG-200 and Receipt of $50 Million Payment

Aileron Therapeutics Announces Presentation of Preclinical Data with ALRN-6924 at the International Society of Experimental Hematology Annual Scientific Meeting

Symic​ ​Bio​ ​Enrolls​ ​First​ ​Patient​ ​in​ ​MODIFY2​ ​Phase​ ​2​ ​Trial​ ​of​ ​SB-061​ ​for​ ​theTreatment​ ​of​ ​Osteoarthritis

Coherus Secures Private Placement from Temasek

Cavion Appoints Spyridon Papapetropoulos, M.D., Ph.D

Phase 2b Results of Viamet’s Oral VT-1161 for the Treatment of Recurrent Vulvovaginal Candidiasis Presented at IDSOG Annual Meeting

Sutro & Celgene to Refocus 2014 Immuno-Oncology Collaboration on Four Programs

Data on VT-1161 for the Treatment of RVVC to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting

Viamet to Present Data on VT-1161 for the Treatment of Onychomycosis at the American Podiatric Medical Association Annual Meeting

Aeglea BioTherapeutics Announces Leadership Change

New Evidence of Sutro ADC’s Potency in Human Tumor Xenografts.

Aeglea BioTherapeutics Appoints James Wooldridge, M.D. as Chief Medical Officer

Symic Bio Appoints Matrix Biology Researcher and Professor Glenn Prestwich as Executive Vice President of Chemistry

Aileron Therapeutics Announces Pricing of Initial Public Offering

Innocrin Pharmaceuticals, Inc. Granted SME Status Designation by the European Medicines Agency

Surface Oncology Expands Scientific Advisory Board with the Addition of Leading Clinical and Translational Cancer Immunotherapy Experts

Coherus Biosciences receives complete response letter from FDA for its biologics license application for CHS-1701 (pegfilgrastim biosimilar candidate)

Viamet’s VT-1598 Demonstrates Potent Activity Against Candida auris and Other Life-Threatening Fungal Species

Viamet Presents Phase 2b Results Demonstrating Unprecedented Efficacy of Oral VT-1161 in the Treatment of Recurrent Vulvovaginal Candidiasis

Anti-tumor Activity Observed in Phase 1 Trial of Novel P53-Targeting Drug ALRN-6924

Protagonist Therapeutics Enters into Worldwide Agreement with Janssen to Co-Develop and Commercialize PTG-200 for Inflammatory Bowel Disease

Protagonist Therapeutics Initiates Phase 1 Study with Novel Hepcidin Mimetic, PTG-300

Aeglea BioTherapeutics Provides AEB1102 Program and Corporate Update

Symic Bio Secures $30 Million Series B Financing and Provides SB-030 Program Update

Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee

Coherus Biosciences prevails in ‘135 IPR decision

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week

FORMA Therapeutics delivers two key objectives in collaboration with Celgene Corporation to advance protein homeostasis medicines to benefit patients.

Innocrin Appoints Fred Eschelman as CEO and is Granted Fast Track for Seviteronel for Cancer Treatment

Sutro ADC Targeting CD74 Eradicates B­Cell Hematologic Malignancy, Prolongs Survival in Tumor Models